, /PRNewswire/ -- I-Mab (NASDAQ: ) (the "Company" or "I-Mab"), a U.S.-based, global biotech company, announced today that the Board of Directors of the Company has appointed Mr.
as the Chairman of the Board of Directors. He succeeds Dr. , who steps down from I-Mab's Board of Directors and the Interim Chairperson position.
Mr. has served as a member of the I-Mab Board of Directors since and is the Chief Executive Officer of CBC Group, a healthcare asset management firm and the founding and largest shareholder of I-Mab. In addition, Mr.
Raj Kannan intends to leave his role as Chief Executive Officer and as a member of the Company's Board of Directors, effective , 2024. Mr. Kannan will stay as an advisor of the Company until to assist with the transition.
This decision follows a mutual agreement with the Board of Directors. Dr. has assumed the role of Interim Chief Executive Officer and a member of the Board of Directors, effective .
In addition to being Interim CEO and Director of I-Mab, Dr. is also an Operating Partner of ABio-X, an incubation platform for life sciences companies. Before joining ABio-X, Dr.
Fu was co-founder and CEO of RVAC Medicines, an mRNA platform company. Prior to founding RVAC, Dr. Fu was Group VP and head of International R&D for Luye Pharma, overseeing organizations in , , , and .
He was also the CEO of GeneLeap, a Luye subsidiary company focused on DNA and RNA therapeutics. Previously, Dr. Fu worked at Merck & Co.
for 15 years with responsibilities co.
